Biologics & Small Molecules Research
Biologics Research and Development
- Measure binding affinity of purified and non-purified biological molecules
- Rapidly perform DOEs to screen optimal assay conditions
The development of Biologics based drugs is an expensive and lengthy process. Early discovery requires researchers to select multiple lead candidates, confirm their mechanisms of action (MOA) against target, and investigate optimal conditions for their production and functional activity before looking into their downstream critical quality attributes. The Octet system provides unmatched ease-of-use and throughput capability in research and assay development for screening and characterization purposes.
Features
ELISA Conversion on the Octet System
While commonplace, ELISA is recognized for variability in results, susceptibility to human error, labor-intensive workflows, and slow time-to-results. Faster times-to-results, better consistency, and less human intervention are the prerequisites for next generation of high throughput laboratory operation. Octet systems are configured to allow researchers to:
- Transfer your ELISA assay onto the Octet system for real-time analysis
- Increase precision over manual ELISA in direct quantitation assays
- Amplify response signals in multistep quantitation assay to increase quantitation sensitivity
High Throughput Phage Display Screening
Phage display is a technique to enable the study of protein, peptide or DNA interactions with a target protein. This molecular tool enables the discovery of high-affinity binders by using bacteriophages to present a target protein on the exterior of the viral coat, while containing the DNA encoding the target protein inside the viral coat. The resulting displaying phages can be screened for binding against a library of peptides or proteins in a high throughput fashion.
Due to its high throughput design, the Octet system is routinely used as a secondary screening platform for Fab fragments and non-antibody ligands derived from phage display libraries. Using immobilized antigen, an Octet system screen can provide affinity ranking data and estimates of association and dissociation constants for each primary hit.
Virus Titer and Vaccine R&D on the Octet System
Bio-analytical tools that aid in the speedy development of new vaccines that can be used to combat the spread of pandemics such as Corona virus (Covid19) are desirable in every cell line development, process development and manufacturing labs. A method for the rapid titer of viruses and for the basic research required for understanding the mechanism of action of molecules involved in a pandemic is critical to the rapid development of a vaccine against the virus.
The Octet instrument is aptly designed to provide the throughput needed to quickly screen antibodies and other biological molecules involved in various virus-related diseases for binding specificity and affinity, epitope binning, neutralization and competition studies and for virus titer. The platform is routinely used for studies and titer determination of viruses and virus like particles including Influenza, Adeno Associated Virus (AAV), Dengue and other viruses and is providing much needed insights in the fight against the Coronavirus.
- High throughput and rapid potency testing
- Quantitate or perform rapid virus affinity characterization
- Develop stability indicating methods
- Study and test intact virus samples
Characterize Irreversible Inhibitors and Measure Commitment to Covalency
The majority of small molecule inhibitor assays tested with label-free, real-time biosensor technologies are reversible interactions, characterized by commonly used kinetic rate models. However, a significant fraction of therapeutic enzyme inhibitors on the market functions through covalent modification of the target.
The Pioneer FE system is a SPR platform that can be used with regenerable Streptavidin biosensors to reversibly capture protein targets and quantify the efficiency of covalent inhibitors binding to the target. The Pioneer FE system's irreversible inhibitor applications method can be used to determine inhibitor compound's commitment to covalency (Cc) as a metric for irreversible inhibitors.
